Pendulum Swings Toward Caution At FDA On New Drug Decisions (New London Day)
Trenton, N.J. Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market, the Food and Drug Administration in recent months has rejected a slew of experimental drugs or delayed their approval and required more data.

Fewer Drug Approvals? Buy! (The Motley Fool)
Stricter standards at the FDA could create a Foolish opportunity.